Allergic asthma treatments
Pro Research Analysisby 
Searched over 200M research papers
Allergic Asthma Treatments: Current Strategies and Innovations
Allergen Immunotherapy (AIT) for Allergic Asthma
Mechanisms and Efficacy of AIT
Allergen immunotherapy (AIT) is a unique treatment for allergic asthma that modifies the immune system to induce long-term tolerance to allergens. Unlike pharmacotherapy, which only controls symptoms, AIT can lead to lasting physiological changes, reducing allergic reactions even years after treatment ends. The primary mechanisms of AIT include changes in immunoglobulin classes (IgA, IgE, and IgG), induction of immunosuppressive regulatory T cells, shifts from helper T cell type 2 to type 1 profiles, and increased production of cytokines like IL-10 and IFN-γ .
Administration Routes and Recommendations
AIT can be administered via subcutaneous injections (SCIT) or sublingual tablets/drops (SLIT). The European Academy of Allergy and Clinical Immunology recommends house dust mite (HDM) SLIT tablets as an add-on treatment for adults with controlled or partially controlled HDM-driven allergic asthma. For children, HDM SCIT and SLIT drops are recommended to decrease symptoms and medication needs .
Pediatric Considerations
In pediatric patients, SCIT has shown moderate evidence in reducing long-term asthma medication use and improving quality of life. SLIT also shows potential benefits, though evidence is less robust. Both treatments are generally safe, with local and systemic allergic reactions being common but anaphylaxis rare .
Pharmacotherapy and Biologic Treatments
Omalizumab for Severe Persistent Allergic Asthma
Omalizumab, a monoclonal antibody targeting IgE, is used as an add-on therapy for severe persistent allergic asthma. It significantly reduces clinically significant exacerbations and improves other asthma-related outcomes. However, its cost-effectiveness remains a concern, with high incremental cost-effectiveness ratios (ICERs) reported .
Targeted Biologic Therapies
Recent advancements in biologic medications have focused on targeting specific cytokines involved in type 2 inflammation, such as IL-4, IL-5, and IL-13. These therapies have shown consistent efficacy in patients with type 2 high asthma, characterized by elevated TH2/type 2 inflammation markers. However, there is a need for novel approaches for patients without type 2 inflammation .
Alternative and Complementary Treatments
Probiotics
Probiotics have shown promise in reducing symptoms and medication use in allergic rhinitis, but their effectiveness in treating asthma remains unproven. Current studies indicate no significant benefits of probiotics for asthma treatment .
Herbal Medicines
Herbal-based treatments have been explored for their potential benefits in asthma and allergic rhinitis. Some medicinal plants have shown positive effects on bronchodilation, pulmonary function, and symptom relief. However, the quality and quantity control of these herbal remedies remain a challenge, and more research is needed to validate their efficacy .
BCG Vaccine
The BCG vaccine has demonstrated potential in preventing or reducing allergen-driven inflammatory responses in animal models by redirecting pathogenic Th2 responses towards protective Th1 and regulatory T cell responses. However, its effectiveness in humans is less clear, necessitating further research .
Conclusion
The treatment landscape for allergic asthma includes a variety of strategies ranging from traditional pharmacotherapy and allergen immunotherapy to emerging biologic treatments and alternative therapies. While AIT offers long-term benefits by modifying the immune response, biologic treatments like omalizumab provide targeted relief for severe cases. Complementary treatments such as probiotics and herbal medicines show potential but require further validation. Continued research and personalized approaches are essential to optimize treatment outcomes for allergic asthma patients.
Sources and full results
Most relevant research papers on this topic
DOI